Global Ovarian Cancer Diagnostics and Therapeutics Market 2019 by Manufactures Analysis: Bristol Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Kazia Therapeutics, Genentech

The ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 13.85% during the forecast period, 2018 to 2023. North America is expected to dominate the global market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.

Get your sample report now @ https://marketprognosis.com/sample-request/17094
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Population of Aged Women
The risk of ovarian cancer is higher in women in the age bracket of 55-64 years. According to the US Census Bureau, women above 60 years of age account for almost 57% of all ovarian cancer incidences and 75% of all ovarian cancer related deaths worldwide, with median age at diagnosis being 63 years and median age at death being 70 years. Thus, the increasing population of aged women is driving the growth of the ovarian cancer diagnostics and therapeutics market.
Additionally, the greater use of combination therapies for the treatment of ovarian cancer and increase in healthcare expenditure in developing countries are fueling the growth of the market.

Key Developments in the Market
• November 2017 - Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
• May 2017 - A new drug developed for ovarian cancer ONX-0801 is in Phase1.

The major players include –
Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Kazia Therapeutics Ltd, Genentech Inc., Astra Zeneca Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/17094
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Lack of Accurate Diagnosis of Ovarian Cancer
Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93%, and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often due to the fact that ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. Additionally, patent expiry of key drugs is also restraining the growth of the ovarian cancer diagnostics and therapeutic market.

North America to Dominate the Market
North America is dominating the market due to the increasing incidence of ovarian cancer. As per the American Cancer Society, was has been estimated that 22,280 new cases of ovarian cancer would be diagnosed in 2017, whereas in 2016, an estimated 20,000 patients were diagnosed with ovarian cancer in the United States alone.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/17094
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.